

Tejaswini Kulkarni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4431419/publications.pdf>

Version: 2024-02-01

33
papers

767
citations

623734

14
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

1593
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. <i>Respiratory Research</i> , 2022, 23, 3.	3.6	1
2	Citrullinated vimentin mediates development and progression of lung fibrosis. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	60
3	Top Ten Tips Palliative Care Clinicians Should Know About Prognostication in Oncology, Dementia, Frailty, and Pulmonary Diseases. <i>Journal of Palliative Medicine</i> , 2021, 24, 1391-1397.	1.1	6
4	Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. <i>Respiratory Medicine</i> , 2021, 189, 106637.	2.9	4
5	Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. <i>PLoS ONE</i> , 2021, 16, e0260345.	2.5	10
6	The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2020, 161, 105821.	2.9	12
7	NATURAL HISTORY OF INTERSTITIAL LUNG DISEASE (ILD) AND RESPONSE TO TREATMENT REGIMENS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM): A SINGLE CENTER EXPERIENCE. <i>Chest</i> , 2020, 158, A1046-A1047.	0.8	0
8	A HIDDEN DIAGNOSIS MANIFESTING AS NONSPECIFIC INTERSTITIAL PNEUMONIA: IGG4-RELATED LUNG DISEASE. <i>Chest</i> , 2020, 158, A2010-A2011.	0.8	0
9	Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. <i>JCI Insight</i> , 2020, 5, .	5.0	39
10	Nintedanibâ€”A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease. <i>US Respiratory & Pulmonary Diseases</i> , 2020, 5, 28.	0.2	0
11	Preoperative Evaluation of Patients With Interstitial Lung Disease. <i>Chest</i> , 2019, 156, 826-833.	0.8	13
12	Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. <i>PLoS ONE</i> , 2019, 14, e0221905.	2.5	31
13	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 199-208.	5.6	90
14	Update in Pulmonary Fibrosis 2018. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 292-300.	5.6	23
15	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L141-L154.	2.9	37
16	WHERE THERE IS NOT SMOKE THERE IS STILL FIRE: A CASE OF PULMONARY LANGERHANS CELL HISTIOCYTOSIS IN A FORMER SMOKER WITH A HISTORY OF MULTIPLE MALIGNANCIES. <i>Chest</i> , 2019, 156, A188.	0.8	0
17	Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat. <i>Current Pulmonology Reports</i> , 2019, 8, 123-130.	1.3	7
18	Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Immunology</i> , 2017, 199, 1596-1605.	0.8	76

#	ARTICLE	IF	CITATIONS
19	Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L928-L940.	2.9	19
20	Alveolar epithelial disintegrity in pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L185-L191.	2.9	52
21	The Impact of Comorbidities on Idiopathic Pulmonary Fibrosis Outcomes. <i>Chest</i> , 2016, 150, 471A.	0.8	1
22	Cost of Hospitalization Among Patients With Idiopathic Pulmonary Fibrosis: Patterns and Predictors. <i>Chest</i> , 2016, 150, 469A.	0.8	2
23	Flexible Bronchoscopy Is Safe and Effective in Adult Subjects Supported With Extracorporeal Membrane Oxygenation. <i>Respiratory Care</i> , 2016, 61, 646-651.	1.6	7
24	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. <i>Respiratory Medicine</i> , 2016, 115, 33-38.	2.9	11
25	Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 861-868.	5.6	30
26	Matrix Remodeling in Pulmonary Fibrosis and Emphysema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 751-760.	2.9	97
27	Extracorporeal membrane oxygenation in adults: A practical guide for internists. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 373-384.	1.3	27
28	Extracorporeal Membrane Oxygenation in Obstructive Lung Diseases Refractory to Conventional Therapy. <i>Chest</i> , 2015, 148, 323A.	0.8	0
29	Safety of Flexible Bronchoscopy in Critically ill Adult Patients Supported With Extracorporeal Membrane Oxygenation. <i>Chest</i> , 2015, 148, 290A.	0.8	0
30	Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L280-L292.	2.9	62
31	Heme Oxygenase-1 Protects Corexit 9500A-Induced Respiratory Epithelial Injury across Species. <i>PLoS ONE</i> , 2015, 10, e0122275.	2.5	15
32	Characteristics of Patients With Pulmonary Venoocclusive Disease Awaiting Transplantation: Comparison With Pulmonary Arterial Hypertension Patients. <i>Chest</i> , 2014, 146, 975A.	0.8	0
33	Loss of Salmeterol Bronchoprotection against Exercise in Relation to ADRB2 Arg16Gly Polymorphism and Exhaled Nitric Oxide. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1407-1412.	5.6	35